内皮型一氧化氮合酶基因G894T多态性与ACEI降压疗效相关性研究

目的探讨原发性高血压患者内皮型一氧化氮合酶基因(eNOS)G894T多态性与血管紧张素转换酶抑制剂(ACEI)降压疗效之间的关系。方法 281例1-2级原发性高血压患者经安慰剂治疗2周后,血压符合入选标准者分别给予咪达普利5～10mg/d或贝那普利10～20mg/d,治疗6周。用酚-氯仿法提取基因组DNA,采用PCR结合限制性内切酶片段长度多态性(RFLP)方法检测eNOS基因型,分析不同基因型组与ACEI降压疗效的关系。结果本研究中eNOS 3种基因型频率分别为GG66.2％、GT27.8％、TT6.0％,等位基因G、T的频率分别为0.80和0.20。ACEI治疗后,eNOS基因GG、GT、TT组收缩压下降值分别为(14.51±11.19)mmHg,(16.11±12.31)mmHg,(12.38±14.30)mmHg;舒张压下降值分别为(8.95±6.56)mmHg,(9.00±6.92)mmHg,(9.37±4.80)mmHg,3组间收缩压与舒张压下降值均无统计学差异。结论 eNOS基因G894T多态性与ACEI降压疗效无关。

Relationship between polymorphism of endothelial nitric oxide synthase gene and antihypertensive efficacy with ACEI

Objective To investigate the relationship between the G894T polymorphism of the endothelial nitric oxide syn- thase (eNOS) in essential hypertensive patients and antihypertensive response to ACE inhibitor. Methods 281 patients with essential hypertension were administered imidapril 5 to 10 mg once daily or benazepril 10 to 20 mg once daily for six weeks, respectively. Genotype of eNOS gene were determined by the polymerase chain re- action (PCR) combined with restriction fragment length polymorphism(RFLP). Results The genotype fre- quencies of eNOS gene were 66.2％ for GG, 27.8％ for GT. and 6.0％ for TT, the allele frequencies for G and T were 0.80 and 0.20. The reductions of SBP in patients carrying GG, GT, and TT genotypes were (14.51± 11.19)mmHg, (16.11±12.31)mmHg, (12.38±14.30)mmHg respectively. The reductions of DBP in pa- tients carrying GG, GT, and TT genotypes were(8.95±6.56)mmHg, (9.00±6.92)mmHg,(9.37±4.80) mmHg, separately. There was no difference in BP reduction among three groups. Conclusions The G894T polymorphism of eNOS gene was not possibly related to the response to ACE inhibitor in essential hypertensive patients.